Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis

According to the World Health Organization (WHO), tuberculosis (TB) remains a global problem with an increasing trend of new cases of TB from 6.1 million in 2015 to 6.3 million in 2016. 1 This global health problem has further worsened in recent years due to the increase in multidrug-resistant tuberculosis (MDR-TB, M. tuberculosis resistant to rifampicin and isoniazid), with an estimated 490 000 new patients in 2016.1 From a health economics perspective, MDR-TB is a heavy burden on health care systems with treatment costs 20 times higher than the corresponding cost of drug-susceptible TB (DS-TB).
Source: Journal of Infection - Category: Infectious Diseases Authors: Source Type: research